Volume 32, No 4, Apr 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 4, April 2022: 375-382   |  Open Access

ORIGINAL ARTICLES

Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters

Yong-Qiang Deng^1,† , Na-Na Zhang^1,2,† , Yi-Fei Zhang^1,3,† , Xia Zhong^4,† , Sue Xu^4,† , Hong-Ying Qiu^1,† , Tie-Cheng Wang⁵ , Hui Zhao¹ , Chao Zhou¹ , Shu-Long Zu¹ , Qi Chen¹ , Tian-Shu Cao¹ , Qing Ye¹ , Hang Chi¹ , Xiang-Hui Duan⁴ , Dan-Dan Lin⁴ , Xiao-Jing Zhang⁴ , Liang-Zhi Xie⁶ , Yu-Wei Gao⁵ , Bo Ying^4,* , Cheng-Feng Qin^1,2,*

¹State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing, China
²School of Medicine, Tsinghua University, Beijing, China
³Kunming University of Science and Technology, Kunming, Yunnan, China
⁴Suzhou Abogen Biosciences Co., Ltd, Suzhou, Jiangsu, China
⁵Key laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun, Jilin, China
⁶Beijing Protein and Antibody R&D Engineering Center, Sinocelltech Ltd, Beijing, China
^†These authors contributed equally: Yong-Qiang Deng, Na-Na Zhang, Yi-Fei Zhang, Xia Zhong, Sue Xu, Hong-Ying Qiu
Correspondence: Bo Ying(bo.ying@abogenbio.com)Cheng-Feng Qin(qincf@bmi.ac.cn)

Monoclonal antibodies represent important weapons in our arsenal to against the COVID-19 pandemic. However, this potential is severely limited by the time-consuming process of developing effective antibodies and the relative high cost of manufacturing. Herein, we present a rapid and cost-effective lipid nanoparticle (LNP) encapsulated-mRNA platform for in vivo delivery of SARS-CoV-2 neutralization antibodies. Two mRNAs encoding the light and heavy chains of a potent SARS-CoV-2 neutralizing antibody HB27, which is currently being evaluated in clinical trials, were encapsulated into clinical grade LNP formulations (named as mRNA-HB27-LNP). In vivo characterization demonstrated that intravenous administration of mRNA-HB27-LNP in mice resulted in a longer circulating half-life compared with the original HB27 antibody in protein format. More importantly, a single prophylactic administration of mRNA-HB27-LNP provided protection against SARS-CoV-2 challenge in mice at 1, 7 and even 63 days post administration. In a close contact transmission model, prophylactic administration of mRNA-HB27-LNP prevented SARS-CoV-2 infection between hamsters in a dose-dependent manner. Overall, our results demonstrate a superior long-term protection against SARS-CoV-2 conferred by a single administra

https://doi.org/10.1038/s41422-022-00630-0

FULL TEXT | PDF

Browse 403